Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Real-world evidence from primary care
Joanna ZJ Ling, Olga Montvida, Kamlesh Khunti, Anthony L Zhang, Charlie C Xue, Sanjoy K Paul
DIABETES OBESITY & METABOLISM | WILEY | Published : 2021
OBJECTIVE: To investigate trends in the prevalence of hypertension and dyslipidaemia in incident type 2 diabetes (T2DM), time to antihypertensive (AHT) and lipid-lowering therapy (LLT), and the association with systolic blood pressure (SBP) and lipid control. RESEARCH DESIGN AND METHODS: Using The Health Improvement Network UK primary care database, 254 925 people with incident T2DM and existing dyslipidaemia or hypertension were identified. Among those without atherosclerotic cardiovascular disease (ASCVD) history and not on AHT or LLT at diagnosis, the adjusted median months to initiating an AHT or an LLT, and the probabilities of high SBP or lipid levels over 2 years in people initiating ..View full abstract
Melbourne EpiCentre gratefully acknowledges the support from the National Health and Medical Research Council and the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS) initiative through Therapeutic Innovation Australia. J.L. has been supported by a RMIT University PhD Scholarship.